Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists


Por: Sanchez-Rovira P, Zamora P, Salvador-Bofill J, Morales S, Martinez-Janez N, Martinez-de-Duenas E, Lluch A, Illarramendi J, Gomez-Pardo P, Gregori J, Garcia-Palomo A, Garcia-Mata J, Fernandez Y, del Barco S, de Juan A, Ciruelos E, Chacon J, Calvo L, Barnadas A, Albanell J

Publicada: 1 ene 2019
Resumen:
Objective: The aim of this survey conducted by 20 leading Spanish oncologists was to analyze the concurrence between Spanish clinical practice and the recently published definition of the optimal sequence for the systemic treatment of metastatic breast cancer (MBC) according to patient profiles. Methods: A self-administered questionnaire was developed, divided into five sections comprising 34 specific questions related to sequential treatments, plus three additional general questions. Respondents were asked to justify negative answers. Participants were recruited randomly by invitation out of a total of 619 oncologists. The questionnaire was sent and collected via e-mail between October 2015 and May 2016. A total of 191 completed questionnaires were received. Results: Overall, 70% of oncologists would keep the three patient profiles exactly as proposed (hormone receptor-positive and HER2-negative, HER2-positive, and triple negative breast cancer). Affirmative answers to questions regarding treatment sequences for these patient profiles (1-34) ranged from 77.8-99.5%, with an average of 90.9% of oncologists being in agreement with the recommended sequential treatments. The lowest degree of consensus was observed for endocrine treatments in pre-menopausal women and for chemotherapy options in hormone-resistant patients, whilst the highest degree of consensus was reached for targeted therapies in HER2-positive patients and for endocrine therapy in post-menopausal women. In their comments, participants revealed a number of economic constraints that prevented them from implementing some of the best treatment options. Conclusions: In conclusion, despite the complexity of MBC treatment, there is general agreement on the optimal treatment sequences.

Filiaciones:
Sanchez-Rovira P:
 Complejo Hosp Jaen, Avda Ejercito Espanol 10, Jaen 23007, Spain

Zamora P:
 Hosp Univ La Paz, Madrid, Spain

Salvador-Bofill J:
 Hosp Univ Nuestra Senora Valme, Seville, Spain

Morales S:
 Hosp Universitari Arnau de Vilanova, Lleida, Spain

Martinez-Janez N:
 Hosp Univ Ramon y Cajal, Madrid, Spain

Martinez-de-Duenas E:
 Consorcio Hosp & Prov Castellon, Castellon de La Plana, Spain

Lluch A:
 Hosp Clin Univ Valencia, Valencia, Spain

Illarramendi J:
 Complejo Hosp Navarra, Pamplona, Spain

Gomez-Pardo P:
 Hosp Univ Vall dHebron, Barcelona, Spain

Gregori J:
 Fdn Inst Valenciano Oncol, Valencia, Spain

Garcia-Palomo A:
 Complejo Asistencial Leon, Leon, Spain

Garcia-Mata J:
 Hosp Santa Maria Nai Ourense, Orense, Spain

Fernandez Y:
 Hosp Univ Cent Asturias, Oviedo, Spain

del Barco S:
 Inst CataladOncol, Girona, Spain

de Juan A:
 Hosp Univ Marques de Valdecilla, Santander, Spain

Ciruelos E:
 Hosp Univ 12 Octubre, Madrid, Spain

Chacon J:
 Hosp Virgen Salud, Toledo, Spain

Calvo L:
 Complejo Hosp Univ A Coruna, La Coruna, Spain

Barnadas A:
 Hosp Santa Creu & Sant Pau, Barcelona, Spain

Albanell J:
 Hosp del Mar, Barcelona, Spain
ISSN: 13699474





Journal Of Drug Assessment
Editorial
TAYLOR & FRANCIS INC, 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 8 Número: 1
Páginas: 62-69
WOS Id: 000469909400001
ID de PubMed: 31069129

MÉTRICAS